We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT00376883
Previous Study | Return to List | Next Study

Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00376883
Recruitment Status : Completed
First Posted : September 15, 2006
Last Update Posted : January 4, 2007
Nordic Cancer Union
Information provided by:
Nordic Myeloma Study Group

Brief Summary:

Multiple myeloma is a malignant hematological disease dominated by monoclonal plasma cells in the bone marrow. Major symptoms are related to the bones due to an increased bone resorption and a decreased bone formation leading to bone pain and increased risk of fractures. The normal osteoclasts are responsible for bone degradation through stimulation from the malignant plasma cells. Bisphosphonates have been shown to inhibit the osteoclast activity but may have serious side-effects due to renal toxicity and the optimal dose have not been established.

In a randomized double blinded design it is aim to compare the standard of monthly injections of 90 mg pamidronate with 30 mg.

The primary end-point is physical function estimated by EORTC QLQ-C30 questionnaire at 12 months after starting the treatment in newly diagnosed treatment demanding multiple myeloma. Secondary end-points are skeletal related events, cost-utility analysis, response, response duration and survival and quality of life with respect to fatigue and pain.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: pamidronate Phase 3

Detailed Description:

Patients with newly diagnosed treatment demanding multiple myeloma are after informed consent and approved inclusion criteria randomised by telephone call to Copenhagen Trial Unit (CTU) and information on the target dose is send to the distributor, Amgros, and the local pharmacy for preparation of the pamidronate solution. Infusion is given for 2½ hours.

Before starting treatment the patient has to fulfil the first EORTC QLQ-C30 questionnaire that is send to the quality of life secretariat in Oslo, Norway. Subsequent questionnaires are mailed directly to the patients every third month.

The infusions are continued for 3 years and may be extended further upon the patient's request.

Every third month the number of skeletal event, the response and complications are recorded.

Skeletal X-rays are performed 9 and 24 months after starting the treatment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 500 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: The Effect of i.v. Bisphosphonate on Health-Related Quality of Life and Skeletal Morbidity for Newly Diagnosed Treatment Demanding Multiple Myeloma. A Prospective Randomised Double Blinded Dose-Effective Study With Cost-Utility Analysis.
Study Start Date : January 2000
Study Completion Date : October 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma

Primary Outcome Measures :
  1. Physical function at 12 months estimated by EORTC QLQ-C30 questionnaire

Secondary Outcome Measures :
  1. Skeletal related event (time to first SRE)
  2. Cost-utility analysis
  3. Subgroup analysis (conventional chemotherapy vs. high dose chemotherapy with stem cell support)
  4. Response, recons duration, survival
  5. Quality of Life estimated by fatigue and pain according to EORTC QLQ-C30

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • New diagnosed multiple myeloma with treatment demanding disease

Exclusion Criteria:

  • Life-expectancy less than 3 months, another active malignant disease, treatment with bisphosphonates for more than 3 months within the last 6 months, patients with creatinine above 400 µmol/l 4 weeks after starting chemotherapy, patients who cannot cooperate for monthly infusions, patients who do not give their informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00376883

Layout table for location information
Department of Haematology B, Aalborg Hospital, University of Aarhus
Aalborg, Denmark, 9000
Department of Haematology, Herlev University Hospital
Herlev, Denmark, 2730
Department of Hematology L, Rigshospitalet
København Ø, Denmark, DK-2100
Hæmatologisk afd., Århus Universitetshospital
Århus, Denmark, DK-8000
Hematologisk seksjon, med avd, Haukeland Universitetssykehus
Bergen, Norway, N-5021
Hematologisk avdeling Ullevål Sykehus
Oslo, Norway, N - 0407
Med avd B, Hematologisk seksjon, Universitetssykehuset Nord Norge
Tromsø, Norway, N-9038
Hematologisk seksjon, St.Olav Hospital
Trondheim, Norway, N-7006
Sahlgrenska Universitetsjukhuset Östra
Gothenburg, Sweden, SE-416 85
Hematologkliniken, Universitetssjukhuset
Linköping, Sweden, SE-581 85
Medicinklin, Universitetssjukhuset MAS,
Malmö, Sweden, SE-205 02
Medicinklin, sekt för hematologi, Norrlands Universitetssjukhus
Umeå, Sweden, SE-901 85
Medicinklinikken Akademiska sjukhuset
Uppsala, Sweden, SE-751 85
Medicinkliniken, Universitetssjukhuset
Örebro, Sweden, SE-70185
Sponsors and Collaborators
Nordic Myeloma Study Group
Nordic Cancer Union
Layout table for investigator information
Principal Investigator: Peter Gimsing, Ass. prof. Nordic Myeloma Study Group
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00376883    
Other Study ID Numbers: NMSG 08/00
NCU D3-98
First Posted: September 15, 2006    Key Record Dates
Last Update Posted: January 4, 2007
Last Verified: January 2007
Keywords provided by Nordic Myeloma Study Group:
multiple myeloma
pamidronate prophylaxis
dose comparison
quality of life
skeletal event
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Bone Density Conservation Agents
Physiological Effects of Drugs